A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma

A phase IIa proof-of-concept, placebo-controlled, randomized, double-blind, crossover, single-dose clinical trial of a new class of bronchodilator for acute asthma

Abstract Background This study evaluates a novel bronchodilator, S1226, for its efficacy in reversing allergen-induced bronchoconstriction in subjects with mild, allergic asthma. S1226 is a new class of bronchodilator that is an aerosol/vapor/gas mixture combining pharmacological and biophysical pri...

Full description

Bibliographic Details
Main Authors: Veronica Swystun, Francis H. Y. Green, John H. Dennis, Emmanouil Rampakakis, Gurkeet Lalli, Morenike Fadayomi, Andrea Chiu, Grishma Shrestha, Sharif Galal El Shahat, David Evan Nelson, Tamer Y. El Mays, Cora A. Pieron, Richard Leigh
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Trials
Subjects:
Novel bronchodilator
Asthma
S1226
Carbon dioxide (CO2)
Perflubron
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s13063-018-2720-6

Internet

http://link.springer.com/article/10.1186/s13063-018-2720-6

Similar Items